By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 143.60 |
Change Today | $ 2.25 |
% Change | 1.59 % |
52 Week High | $201.44 |
52 Week Low | $118.84 |
Volume | 44 |
Shares Issued | 145.80m |
Market Cap | $20,937m |
RiskGrade | 259 |
Strong Buy | 7 |
Buy | 6 |
Neutral | 20 |
Sell | 1 |
Strong Sell | 0 |
Total | 34 |
Time | Volume / Share Price |
15:59 | 100 @ $143.63 |
15:59 | 100 @ $143.65 |
15:59 | 200 @ $143.66 |
15:59 | 100 @ $143.65 |
15:59 | 100 @ $143.57 |
You are here: research